NCT02551159 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02551159
Title	Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN
Acronym	KESTREL
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	laryngeal squamous cell carcinoma oropharynx cancer hypopharynx cancer oral squamous cell carcinoma head and neck squamous cell carcinoma
Therapies	Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab
Age Groups:	adult
Covered Countries	USA \| SVK \| ROU \| POL \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT

NCT02551159
Clinical Trial Detail